Ipsen to Acquire Kartos for Up to $1.75 Billion, Heating Up Race in Later-Line Myelofibrosis Treatment

For patients with myelofibrosis, treatment is often not a simple distinction between “having a drug available” and “having no drug available,” but whether existing drugs can reduce splenomegaly, fatigue, night sweats, and pain enough to change daily life. Ipsen’s decision to acquire the U.S. biotech company Kartos Therapeutics is a bet on this still insufficiently met clinical space.

Ipsen announced on June 29, 2026, that it will acquire Kartos for an upfront payment of $450 million, with up to $1.3 billion in milestone payments, bringing the potential total value of the transaction to $1.75 billion. The transaction remains subject to customary closing conditions, including the expiration of the U.S. Hart-Scott-Rodino antitrust waiting period; company materials also list Orrick as Ipsen’s legal adviser, while Kartos is advised financially by Goldman Sachs and PJT Partners and legally by DLA Piper.

The core asset in the acquisition is navtemadlin, an oral MDM2 inhibitor. It is currently being evaluated in the Phase III POIESIS trial as an add-on therapy to ruxolitinib in patients with intermediate- to high-risk, TP53 wild-type myelofibrosis; Ipsen said topline results are expected in 2027. If the trial succeeds, navtemadlin could address a group of patients who have already received JAK inhibitors but have had an inadequate response or continue to carry a symptom burden.

MDM2 is an important regulator of the tumor suppressor protein p53. The concept behind inhibiting MDM2 is to re-release p53-mediated cellular stress and death signals in tumor cells in which TP53 has not yet been disabled by mutation. However, this mechanism also makes patient selection especially critical; the trial’s focus on the TP53 wild-type population reflects alignment between the biological hypothesis and the clinical development strategy.

According to attachment materials released the same day, POIESIS is a global Phase III study designed to enroll more than 600 patients at over 250 centers. That scale shows Ipsen is not taking over an early exploratory program, but a clinical asset that has already entered a pivotal validation stage; it also means the real point of judgment will be the efficacy and safety data in 2027, not the transaction value itself.

Ipsen and Kartos also cited earlier Phase Ib/II data from KRT-232-109, referring to spleen volume and symptom response measures at week 24 in 19 patients with a poor response to ruxolitinib. However, the number of patients in these data is limited, making them more suitable for supporting the rationale for further trials and still insufficient to presume the Phase III outcome in advance. For serious clinical development, there remains a distance between early signals and approvable evidence.

For Ipsen, Kartos provides a path that could change the shape of its hematologic oncology pipeline in the near term. For the myelofibrosis field, the deal underscores that drugmakers are looking for treatment combinations beyond or on top of JAK inhibitors. The next key question is not whether the MDM2 inhibitor concept is novel, but whether navtemadlin can prove in a large, controlled trial that adding an oral drug can truly give patients a clear and tolerable clinical benefit.